Headway in Hepatology: Resmetirom’s Historic FDA Approval, What’s Next in MASH

For many years, metabolic dysfunction-associated steatohepatitis (MASH) was a clinical enigma – prevalent, progressive, and without a targeted treatment. That narrative changed in 2024, a year that will undoubtedly be remembered as a turning point in hepatology when the US Food and Drug Administration (FDA) granted accelerated approval to resmetirom (Rezdiffra).¹